Liver Transplant Clinical Trial
— OLP-IIOfficial title:
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
OLP-II Registry is a sponsor-initiated, multi-center, observational, post-approval registry.
Status | Recruiting |
Enrollment | 10000 |
Est. completion date | September 2033 |
Est. primary completion date | September 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | All liver transplant recipients who are transplanted with an OCS-perfused donor liver are eligible for the Registry. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan Medical Center | Ann Arbor | Michigan |
United States | Emory University Hospital | Atlanta | Georgia |
United States | University of Alabama | Birmingham | Alabama |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Lahey Clinic Medical Center | Burlington | Massachusetts |
United States | Carolinas Medical Center/Atrium Health | Charlotte | North Carolina |
United States | UT Southwestern Medical Center | Dallas | Texas |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Duke Medical Center | Durham | North Carolina |
United States | Houston Methodist | Houston | Texas |
United States | Mayo Clinic Hospital Florida | Jacksonville | Florida |
United States | University of California San Diego | La Jolla | California |
United States | NY Presbyterian Hospital/Columbia Univ. Medical Center | New York | New York |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | Mayo Clinic Hospital Arizona | Phoenix | Arizona |
United States | SSM Health Saint Louis University Hospital | Saint Louis | Missouri |
United States | University Hospital, University of Texas Health Science Center | San Antonio | Texas |
United States | University of California San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
TransMedics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | 1-year patient survival with the originally transplanted liver (patient and graft survival) post-liver transplant. | 1-year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
Completed |
NCT01696331 -
Text Messaging for Adherence in Adolescent Liver Transplant Recipients
|
N/A | |
Recruiting |
NCT05051605 -
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
|
||
Completed |
NCT01598987 -
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
|
Phase 3 | |
Active, not recruiting |
NCT05074160 -
OCS Liver Perfusion (OLP) Post-Approval Registry
|
||
Completed |
NCT05087550 -
Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
|
||
Recruiting |
NCT04836923 -
LIFT Intervention in Liver Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT03666689 -
Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
|
||
Not yet recruiting |
NCT06088758 -
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
|
N/A | |
Terminated |
NCT01230502 -
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
|
N/A | |
Completed |
NCT00171509 -
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT06075745 -
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
|
Phase 2 | |
Completed |
NCT02057484 -
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
|
||
Active, not recruiting |
NCT03577431 -
Liver Transplantation With Tregs at MGH
|
Phase 1/Phase 2 | |
Recruiting |
NCT06342557 -
Transitional ePRO Diary Liver
|
||
Not yet recruiting |
NCT04265157 -
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
|
||
Recruiting |
NCT02863250 -
Australian and New Zealand Massive Transfusion Registry
|
||
Completed |
NCT00698399 -
Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients
|
N/A |